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This issue of the Stem Cell International journal contains
papers from many of the leading scientists in the emerging
ﬁeld: ex vivo expansion of hematopoietic progenitor cells
into erythrocytes for transfusion.
Bloodtransfusion,theﬁrstformofsuccessfulcelltherapy
and, at least to some, “transplantation”, was inspired by
the discovery of the circulation by Richard Harvey in the
1600s [1] and begun in earnest later in that century. The
development of this clinical practice into the safe and
routine therapy we all know today has been both an exciting
scientiﬁc adventure and the foundation for a number of
otherscientiﬁcdisciplines.Morespeciﬁcally,theimmunology
of transfusion and transplantation began with the discovery
of the heterogeneity of human blood group antigens by
Dr. Karl Landsteiner in 1901 (recognized with a Nobel
Prize in 1930). The discovery of clinically relevant infectious
diseases transmitted by transfusion played an important
role in the development and advancement of virology.T h e
inheritanceofcertainformofanemiaswasdiscoveredduring
blood transfusion practice and led to development of the
genetics of human red cell disorders. In the 1940–1950s, the
establishment of blood banks followed by the development
of rigorous donation criteria and standardization of blood
manufacturing processes has made transfusion safe and
widely available and has provided a paradigm for the
development of emerging therapies using ex vivo expansion
and diﬀerentiation of many cell types. An example of one
such therapy is represented by the tumor immunotherapy
described by Lapteva and Vera.
The blood supply of industrialized countries is adequate
overall. Nearly one hundred million donations are made
every year worldwide (http://www.who.int/mediacentre/
factsheets/fs279/en/index.html). The availability of blood
and blood products in these nations has permitted the
development and implementation of numerous life-saving
surgical procedures (open heart surgery, organ transplanta-
tion, damage control resuscitation for trauma, and others)
and cancer treatments which were not even imaginable
without assurance that blood for transfusion would be
readilyavailableandsafe.However,bloodisnotanunlimited
resource and its potential need as the world rapidly develops
requires a signiﬁcant increase in blood donation. By some
estimates (CDH), given the world’s population and given the
per capita transfusion of Canada as a utilization benchmark,
nearly 250 million whole blood donations would be needed.
Furthermore, and despite its high level of safety, human
donated, unit-by-unit-derived blood donation/transfusion
(i.e.,withoutbatchedbloodmanufacturingintoanaliquoted
and homogenized pharmaceutical product), still leads to
morbidityandmortalityofitsownaccordandhassigniﬁcant
variation from product to product based on the nature of
the collection, manufacturing and storage processes, and
the antigenic variation of any given donor, amongst others.
Finally, it is not known what eﬀect the aging of the world’s
population will have both on per capita utilization and on
the ability of the smaller, younger populations to donate [2].
Theseissues,andthenearly20-year-oldsearchforalternative
products to meet the transfusion need are discussed in the
paper by Whitsett et al.
Scientiﬁc research is inspired by the prospect of a clinical
goal. In recent years, a revolution in stem cell biology
has occurred that has far reaching implications, speciﬁcally,2 Stem Cells International
the discovery that it is possible to generate a potentially
unlimited supply of stem cells by epigenetic/genetic treat-
ments of somatic cells (T cells, ﬁbroblasts, others) from
any individual (see Pourcher et al., Hyroyama et al., and
Chang et al.). In addition, techniques have been discovered
to reprogram any cell into another cell type avoiding the
induction of pluripotency. These techniques are fascinating
though there are numerous scientiﬁc, safety, and scaling-up
issues to be resolved before cells which have been genetically
“altered” in the laboratory may be considered ready for
widespread clinical use. As red blood cells do not have a
nucleus, it is possible that they will be accepted as genetically
safe. Indeed, it is this notion that supports that red blood
cells from Hematopoietic stem/progenitor cell expansion or
rediﬀerentiation may represent the ﬁrst therapeutic product
to be generated by genomic reprogramming technology.
Reprogramming technology is still under development.
Therefore, red blood cells expanded ex vivo from primary
stem cell sources currently discarded (buﬀyc o a t sp r o d u c e d
during the blood manufacturing processes and low-volume
umbilical cord blood) are being considered for ﬁrst-in-man
studies. Tirelli et al. identify the cell populations present in
adult blood which are responsible for massive production of
red blood cells ex vivo. The ﬁrst-in-man proof-of-principle
study for the use of in vitro expanded red blood cells
for transfusion was reported on September 1st 2011, by
Luc Douay and colleagues [3], who have also coauthored
Pourcher et al. This paper reported that red blood cells
generated in vitro from mobilized CD34pos cells collected by
apheresishavenormalsurvival(determinedby 51Crlabeling)
when transfused into an autologous recipient [3]. This ﬁrst-
in-manautologoustransfusiondescribedalsowhatwouldbe
the most likely safety data necessary for a larger clinical study
with such products [in vitro characterization (blood group
antigen expression proﬁling, deformability, hemoglobin
content and O2 dissociation curves) and in vivo functional
studies in animal models (survival and morphology);
http://www.clinicaltrials.gov/ct2/show/NCT00929266]. In
vivo functional studies of human red blood cells in animal
models will likely allow more complete characterization
in many ways [4]. Ghinassi et al. describe an improved
animal model which allows in vivo imaging and cell fate
determination of human erythroid cells by labeling the
cells before transfusion with a ﬂuorescent reporter gene by
retroviral technology.
Although red blood cells do not have nuclei, their
immediate precursors the erythroblasts do. The terminal
maturation of erythroblasts into functional red cells requires
a complex remodeling process which ends with extrusion of
the nucleus and the formation of an enucleated red blood
cell [5]. These late stages of maturation are intrinsically
controlled by epigenetic/genetic expression programs of the
erythroblast itself. Cell reprogramming methodologies may
(and at present appear to) disrupt these programs, leading
to ineﬃcient enucleation. Keerthivasan et al. discuss novel
insights into the critical mechanisms of terminal maturation
of a red blood cell and strategies to improve the eﬃciency of
these processes.
As represented by all the information, data, and in fact
vision contained in this issue, we are clearly at the beginning
of a rapidly expanding ﬁeld. The papers herein provide a
broad and comprehensive overview of the most relevant
areas of research which have been pursued and are needed
to advance the ﬁeld. Still, as state of the art as this issue is
presently, the ﬁeld is moving so rapidly that one may predict
that new knowledge will rapidly follow.
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